Neumora Therapeutics, Inc. financial data

Symbol
NMRA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 200, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -114 % -501%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 159M shares
Common Stock, Shares, Outstanding 159M shares +387%
Common Stock, Value, Issued 16K USD
Weighted Average Number of Shares Outstanding, Basic 158M shares +439%
Weighted Average Number of Shares Outstanding, Diluted 158M shares +439%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 45.8M USD +55.2%
General and Administrative Expense 14.3M USD +47.9%
Operating Income (Loss) -60.1M USD -53.4%
Nonoperating Income (Expense) 6.35M USD +79.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -236M USD -80%
Income Tax Expense (Benefit) 268K USD
Net Income (Loss) Attributable to Parent -254M USD -106%
Earnings Per Share, Basic -0.34 USD/shares +72.1%
Earnings Per Share, Diluted -0.34 USD/shares +72.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 183M USD -13.3%
Marketable Securities, Current 240M USD
Assets, Current 443M USD
Property, Plant and Equipment, Net 1.64M USD
Operating Lease, Right-of-Use Asset 4.28M USD
Assets 450M USD
Accounts Payable, Current 1.49M USD
Employee-related Liabilities, Current 4.66M USD
Accrued Liabilities, Current 19.5M USD
Liabilities, Current 24.6M USD
Operating Lease, Liability, Noncurrent 938K USD
Liabilities 25.7M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -148K USD
Retained Earnings (Accumulated Deficit) -757M USD
Stockholders' Equity Attributable to Parent 425M USD
Liabilities and Equity 450M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43M USD -30%
Net Cash Provided by (Used in) Financing Activities 1.85M USD +1727%
Net Cash Provided by (Used in) Investing Activities -150M USD -5425%
Common Stock, Shares Authorized 700M shares -42.1%
Common Stock, Shares, Issued 159M shares +387%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -191M USD -534%
Deferred Tax Assets, Valuation Allowance 197M USD +39.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 199M USD +38.4%
Operating Lease, Liability 5.23M USD
Payments to Acquire Property, Plant, and Equipment 117K USD -77.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -53.8M USD -53%
Lessee, Operating Lease, Liability, to be Paid 5.61M USD
Property, Plant and Equipment, Gross 3.18M USD +7.68%
Operating Lease, Liability, Current 3.49M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.89M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.72M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 380K USD
Deferred Tax Assets, Operating Loss Carryforwards 79.1M USD +23.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 8.66M USD +5.97%
Operating Lease, Payments 4.07M USD +63.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 158K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.5M USD -28.3%
Share-based Payment Arrangement, Expense 7.37M USD +236%